Harry L.A. Janssen is Professor of Medicine at the University of Toronto, Ontario, Canada, where he holds the Francis Family Chair in Hepatology. He currently works at Toronto General Hospital as Chief of Hepatology and Director of the Toronto Centre for Liver Disease.
Dr. Janssen graduated from medical school in Nijmegen, The Netherlands. During his study he spent one year as research fellow in Hepatology at the Mayo Clinic. He obtained his PhD in Rotterdam on the role of immune modulating therapy in chronic hepatitis B. Following his training in Internal Medicine in Leiden and Gastroenterology at the Erasmus University in Rotterdam, he returned to the Mayo Clinic for a Research Fellowship in Hepatology at the Center of Basic Research in Digestive Diseases. In 2001 he became a faculty member and in 2006 he was appointed as full Professor of Hepatology at the Erasmus University and Chief of the Section Liver Diseases and Transplantation at the Erasmus Medical Center in Rotterdam. After a successful career in Rotterdam he moved in 2013 to Canada to head the Liver Program at Toronto Western Hospital. In 2016 he merged all three Toronto Liver Programs into the Toronto Centre for Liver Disease to become the biggest liver program in North America, based at Toronto General Hospital, University Health Network.
Dr. Janssen has coordinated numerous global multicenter studies on the natural history and treatment for chronic viral hepatitis and other liver diseases. His clinical and translational research aiming for immunological control and cure of hepatitis B and C have led to several globally used novel treatment concepts. Based on publications and citations he is currently ranked as the nr.1 global expert in chronic hepatitis B (Expertscape, Sept. 2020). His research contributions include sustained federal funding (greater than 20 years), over 500 peer reviewed publications, an H-index of more than 100, and over 45,000 citations (Google Scholar). He has acquired over $50 million USD in research funding from many different organizations such as NIH, European Commission, CIHR, NWO and ZonMW. He has received several prestigious international awards and has mentored over 50 PhD students, many of whom have taken leadership positions in the field of Hepatology or Virology. In addition to his longstanding expertise in antiviral therapy of chronic viral hepatitis, he is a leading scientist in the field of vascular disorders of the liver. Dr. Janssen is a member of the EASL Guideline Committees for both Hepatitis B and for Vascular Liver Disease. He currently serves as the Head of the Division of Experimental Therapeutics at the Toronto General Hospital Research Institute (TGHRI), Vice Chair of the AASLD Special Interest Group (SIG) for Hepatitis B and the Global Chair of the International Symposium on Viral Hepatitis and Liver Disease (ISVHLD).